Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Apr 01, 2009 (Vol. 29, No. 7)

Bad Science

URL:www.badscience.net
  • Excellent articles
  • Nothing significant
Dr. Ben Goldacre has something on his mind. Maybe he is contemplating having his other ten strands of DNA activated over the Internet (did you know you have twelve strands already?) for the bargain price of $39. Far more likely, though, he is pondering the preposterousness of pseudoscience, the likes of which have a way of creeping into the media and the spam folders of our inboxes. (Miracle weight loss pill, anyone?) No scientific charlatan is safe from Dr. Goldacre’s critiques and sarcastic condemnations, which comprise his “Bad Science” column for the British newspaper, The Guardian. On this site you’ll find all of these columns, archived from 2003. In addition, you too can join the lively conversation, posting comments in response to the myriad topics included on the site. So the next time you’re tempted to take your Paypal account for a spin over some online nucleic acid activation, you might try checking out this page first
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »